{"filings":[{"id":2410956,"accession_number":"0001493152-26-039708","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2026-08-21T20:42:03+00:00","items":["5.02","9.01"],"status":"ready","headline":"NexGel terminates CEO Adam Levy, appoints Brian Kieser interim CEO, launches strategic review","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Adam R. Levy terminated as CEO without cause effective Aug 21, 2026; resigned from board and all officer positions.","Brian Kieser appointed Interim CEO effective Aug 21, 2026; is CEO of Fountainhead Lifesciences and board member since May 6, 2026.","Board formed Special Committee for Strategic Review and Value Creation (Kevin Harris, Chair; Steve Glassman) to assess operations.","Committee authorized to evaluate divestiture, partnerships, restructuring or wind-down of non-core assets; initial framework expected in 30-45 days.","Levy to provide 90-day transition assistance; Separation Agreement terms not yet finalized, with 8-K amendment to follow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2283039,"accession_number":"0001493152-26-038637","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2026-08-17T12:15:29+00:00","items":["2.02","9.01"],"status":"ready","headline":"NexGel Q2 2026: revenue $3.69M, net loss $2.87M; BioNX backlog $795K; proxy vote fails","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $3.69M, net loss $2.87M; includes $756,554 BioNX amortization, $273,710 transaction costs, $144,495 SilverSeal recall.","BioNX Surgical backlog ~$795K due to supply chain; Sequence transferring manufacturing to San Antonio, TX.","Proxy vote failed to increase authorized shares/reverse split; will resolicit standalone, engaged Alliance Advisors, target late Sept.","$710K restricted cash from ATW Partners released and returned post-quarter; relationship concluded.","Launched BioNX Regenerative Eye Health & Aesthetics, led by Shaun Mullen; SilverSeal recall supports hospital launch in August."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":6336000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2080963,"accession_number":"0001493152-26-036206","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2026-08-05T21:00:14+00:00","items":["5.07","9.01"],"status":"ready","headline":"NexGel annual meeting: reincorporation, share increase, reverse split all fail","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected; Scott R. Henry resigned effective July 1, 2026.","Proposal to reincorporate from Delaware to Nevada failed (1.76M for, 2.01M against).","Authorized share increase from 25M to 100M rejected (3.19M for, 512k against).","Reverse stock split (1:2 to 1:10) not approved (2.89M for, 830k against).","Issuance of shares for convertible notes/warrants approved; say-on-pay and auditor ratified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1943200,"accession_number":"0001493152-26-035258","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2026-07-29T21:25:00+00:00","items":["5.02","9.01"],"status":"ready","headline":"NexGel enters new CEO employment agreement with Adam Levy; base salary $375K, option grant of 160K shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Adam Levy receives base salary of $375,000 per year under new employment agreement effective July 23, 2026.","Eligible for discretionary cash bonus up to $25,000 for FY2026 and EBITDA-based bonus up to 50% of base salary.","Granted options to purchase 160,000 shares at $0.647; 40,000 vest Dec 31, 2026, remainder monthly over 36 months.","Severance includes 12 months base salary, pro-rata bonus, COBRA, and equity acceleration on qualifying termination.","Enhanced severance on change-in-control termination: lump sum of 1x base salary plus 100% target bonus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1553677,"accession_number":"0001493152-26-032687","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2026-07-09T20:15:25+00:00","items":["8.01"],"status":"ready","headline":"NexGel postpones 2026 Annual Meeting to July 31 for proxy solicitation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting postponed from July 10 to July 31, 2026 at 10:00 a.m. ET.","Postponement allows additional time to solicit proxies for requisite stockholder vote on proposals.","Record date unchanged; previously submitted proxies remain valid unless revoked.","Agenda and proposals unchanged from definitive proxy statement filed June 9, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1417396,"accession_number":"0001493152-26-031962","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2026-07-02T21:15:31+00:00","items":["5.02"],"status":"ready","headline":"NexGel director Scott Henry resigns effective July 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Henry notified NexGel of his resignation from the Board, effective July 1, 2026.","Henry served as Chair of the Audit Committee and member of Compensation and Nominating/Governance Committees.","Resignation is to lighten his schedule and focus on other business ventures and personal matters.","Company states resignation is not due to any disagreement with NexGel or its subsidiaries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1112596,"accession_number":"0001493152-26-029100","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2026-06-17T20:45:24+00:00","items":["7.01","9.01"],"status":"ready","headline":"NexGel releases updated investor presentation for June 2026","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company began using a new investor presentation dated June 2026.","Filing text contains no specific financial figures or guidance changes.","Investor presentation content not available in the provided exhibit extract."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":471676,"accession_number":"0001493152-26-023851","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2026-05-15T20:31:01+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"NexGel closes $1.21M private placement of convertible notes and warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1.21M aggregate principal amount of unsecured convertible notes at $0.60/share initial conversion price.","Issued warrants to purchase 1,008,334 shares of common stock at $0.80/share, expiring 5 years from issuance.","Proceeds to be used for working capital; Alere Financial Partners acted as placement agent.","Affiliates purchased $1.085M of the offering: director Brian Kieser $1M, CEO Adam Levy $60k, director Scott Henry $25k.","Registration rights agreement requires filing of resale registration statement within 75 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":41248,"accession_number":"0001493152-26-022503","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2026-05-12T20:30:25+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"NEXGEL appoints two Sequence LifeScience leaders to board; Sequence led $5.5M financing","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian J. Kieser (CEO) and Kevin M. Harris (COO) of Sequence LifeScience appointed to NEXGEL board effective May 6, 2026.","Sequence led $5.5M convertible note financing ($0.60/ share conversion, $0.80 warrant) to close Celularity acquisition.","Kieser individually issued $1M convertible note (same terms: $0.60 conversion, $0.80 warrant) on May 11, 2026.","Kieser is indirect sole owner of Sequence; Harris is COO with no equity in Sequence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93017,"accession_number":"0001493152-26-020657","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"NexGel appoints Ian Blackman as CFO; Adam Drapczuk resigns as interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ian Blackman appointed CFO effective April 27, 2026; CPA with over 30 years of finance leadership experience.","Base salary of $250,000; cash bonus tied to EBITDA tiers: 10% at $4M, 30% at $6M, 50% at $8M.","Received initial option grant for 160,000 shares, 5-year term, vesting over 4 years with acceleration upon change in control.","Press release links appointment to advancing Celularity acquisition: definitive agreement to license/acquire regenerative biomaterial products from Celularity (NASDAQ: CELU).","Adam Drapczuk resigned as interim CFO with no disagreement; will continue providing consulting services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93016,"accession_number":"0001493152-26-018962","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"NexGel receives Nasdaq deficiency notice for bid price below $1; 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price of common stock (NXGL) below $1.00 for 30 consecutive business days.","Company has until October 19, 2026 to regain compliance per Nasdaq Rule 5810(c)(3)(A).","Compliance possible if bid price closes at $1.00+ for 10 consecutive days before deadline.","If not cured, a second 180-day compliance period may be available subject to conditions.","Company may consider a reverse stock split; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93015,"accession_number":"0001493152-26-018302","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["1.01","2.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"NexGel closes Celularity regenerative biomaterials acquisition; expects revenue to triple to ~$35M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired Celularity's regenerative biomaterials portfolio for $13.3M ($8.3M cash + $5M convertible note); closed April 17, 2026.","Raised $6.9M via convertible notes (10% interest, 18-month, $0.60 conversion) and warrants (5-year, $0.80 strike) to fund the deal.","Strategic partner Sequence LifeScience invests $5.5M; will serve as contract manufacturer and collaborate on new products.","Transaction expected to triple annual revenue to ~$35M pro-forma and be immediately accretive to profitability.","Launched BioNX Surgical division; planned 510(k) filings in 2026, 2027, 2028 for three new products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104296,"accession_number":"0001493152-26-009474","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"NEXGEL signs $35M deal to buy Celularity's biomaterial portfolio; expects revenue to triple to ~$35M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Consideration up to $35M: $15M upfront plus $20M in milestone payments tied to net sales.","Deal expected to triple annual revenue to ~$35M and make NEXGEL immediately profitable upon closing.","Acquisition includes 6 commercial-stage regenerative products with existing reimbursement, plus 3 planned 510(k) filings through 2028.","Experienced commercial and scientific team from Celularity is expected to join NEXGEL, expanding sales reach.","NEXGEL also disclosed discussions for a $100M equity line of credit facility with a third-party investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104295,"accession_number":"0001493152-26-006124","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"NexGel closes $1.8M Series A convertible note; up to $14.9M more for Q1 acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial Series A convertible note raised $1,797,381 gross proceeds, bearing 10% interest (18% on default), convertible at $1.244/share with floor $0.2488.","Proceeds reserved for an approved acquisition; if acquisition closes by April 15, 2026, investor must buy Series B notes up to $14,869,286.","Series B issuance conditioned on shareholder approval: redomestication to Nevada, reverse split up to 250:1, authorized shares increase to 250M from 25M.","Convertible notes are senior secured on all company assets; proceeds returned to investor if acquisition not consummated.","Palladium Capital Group acted as placement agent with 7% cash fee and warrants for 7% of shares sold in the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104294,"accession_number":"0001493152-26-004535","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Nachum Stein resigns from NexGel board effective February 2, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nachum Stein notified NexGel on January 29, 2026 of his resignation as Board member, effective February 2, 2026.","Stein served as Chairperson of the Board's Compensation Committee.","Resignation is to lighten his schedule and focus on other business ventures, not due to any disagreement with the company.","Resignation letter dated January 29, 2026 filed as Exhibit 17.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104293,"accession_number":"0001493152-26-000813","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NexGel appoints Adam Drapczuk as Interim CFO, replacing Joseph McGuire effective Jan 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Adam Drapczuk appointed Interim CFO effective Jan 1, 2026; succeeds Joseph F. McGuire terminated Dec 31, 2025.","Drapczuk previously served as CFO from June 2021 to Dec 2024 and as financial consultant in 2025.","Annual cash compensation $200,000; company owes ~$93,000 from prior consulting; equity grant pending.","McGuire's separation terms pending, will be disclosed in 8-K/A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120590,"accession_number":"0001493152-25-027245","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["7.01","2.02","9.01"],"status":"ready","headline":"NexGel spins off drug delivery program into NexGelRx; shareholders get 19.99% equity stake","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NEXGEL spins off select Rx drug delivery assets into new entity NexGelRx; retains 19.99% non-dilutive equity stake.","NEXGEL will receive a 5% global royalty in perpetuity on products sold using its drug delivery technology.","NexGelRx closed initial funding from outside investors; NEXGEL will be exclusive manufacturer of hydrogel for NexGelRx.","Dr. Jerome Zeldis, NEXGEL director who helped bring 10 pharma products to market, will also serve on NexGelRx board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120589,"accession_number":"0001493152-25-024829","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NexGel cancels special meeting; drops proposal to increase authorized shares from 25M to 1B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board voted on Nov 21, 2025 to cancel the Special Meeting scheduled for Nov 26, 2025.","Meeting was called to vote on amending certificate to increase authorized common shares from 25,000,000 to 1,000,000,000.","The Board will no longer pursue stockholder approval of the share increase proposal.","No explanation for the cancellation was provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120588,"accession_number":"0001493152-25-021742","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"NEXGEL Q3 revenue flat at $2.93M; net loss narrows to $0.65M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $2.93M, virtually unchanged from $2.94M in Q3 2024.","Gross margin improved to 42.4% vs 39.3% YoY; gross profit $1.24M.","Net loss attributable to stockholders $0.65M vs $0.69M YoY.","Adjusted EBITDA loss $0.35M, same as Q3 2024; EBITDA loss $0.55M.","Cash + restricted cash ~$1.86M; includes $1M non-dilutive STADA capital."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":8625000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137191,"accession_number":"0001641172-25-023188","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"NEXGEL Q2 revenue doubles to $2.88M, guided to $13M and positive EBITDA for FY2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.88M, +100.3% YoY; gross margin 43.6% vs 20.3% YoY.","Net loss $0.67M, improved from $0.89M YoY; adjusted EBITDA loss $0.42M.","Reiterated FY2025 guidance: $13M revenue and achieving positive EBITDA.","Subsequent: expanded STADA partnership with $1M advance; raised $1.05M gross proceeds.","Cash $0.73M as of June 30; 8,067,580 shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":5690000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137190,"accession_number":"0001641172-25-022240","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"NEXGEL appoints Shutterstock CAO Steve Ciardiello, CPA, to its Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective July 31, 2025; Ciardiello also joins Audit Committee.","Ciardiello has over 25 years of finance leadership; currently CAO of Shutterstock (SSTK).","Granted option to purchase 30,000 shares at $2.25/share, vesting monthly over 12 months.","No other compensation arrangements or related-party transactions disclosed.","Press release announcing appointment issued August 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137189,"accession_number":"0001641172-25-021893","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"NEXGEL raises ~$1M in registered direct offering and private placement; warrants at $4.25","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registered direct offering of 413,044 shares at $2.30/share; gross proceeds ~$950,000.","Concurrent private placement of warrants to buy 206,522 shares at $4.25, 5-year term.","Additional private placement of 45,652 shares to consultant, director, and stockholder for $105,000, with 22,826 warrants.","CEO notes combined with $1M STADA advance, financing strengthens balance sheet for H2 growth.","Closing expected on or before August 5, 2025; Alere Financial Partners acted as placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137188,"accession_number":"0001641172-25-021743","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NexGel furnishes new investor presentation; no material changes disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Began using a new investor presentation on July 31, 2025; furnished as Exhibit 99.1.","Presentation is furnished, not filed, under Regulation FD and not incorporated by reference.","No specific financial or operational updates were provided in the 8-K filing itself."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137187,"accession_number":"0001641172-25-019508","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["7.01","2.02","9.01"],"status":"ready","headline":"NEXGEL expands partnership with STADA; gets $1M non-dilutive capital for N.A. launches","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expansion includes digestive enzyme formulas and scar/stretch mark solutions for North America.","STADA will advance $1 million in non-dilutive capital to support product launches and marketing.","Partnership builds on existing relationship; targets consumer health market in North America.","CEO Adam Levy cites shared opportunity and acceleration of go-to-market strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154476,"accession_number":"0001641172-25-015860","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"NexGel stockholders approve 780K share increase to incentive plan, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Fourth Amendment to 2019 Long-Term Incentive Plan, increasing authorized shares by 780,000 to 1,651,429 total.","Elected five directors: Steven Glassman, Scott Henry, Adam Levy, Nachum Stein, and Dr. Jerome Zeldis to serve until 2026 annual meeting.","Advisory vote on executive compensation passed; frequency set to every year.","Ratified Turner, Stone & Company as independent auditor for fiscal year ending December 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154475,"accession_number":"0001641172-25-013634","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NexGel adopts investor presentation, no material new disclosures","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["New investor presentation used starting June 4, 2025; attached as Exhibit 99.1.","Presentation does not contain new financial results, guidance, or material events.","Company is an emerging growth company; no operational updates provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154474,"accession_number":"0001641172-25-009954","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NexGel Q1 revenue $2.81M (+121% YoY); gross margin expands to 42.4% from 12.6%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.81M, up 121% YoY from $1.27M; guided Q1 slightly above prior outlook.","Gross profit margin 42.4% vs 12.6% in Q1 2024 and 37.2% in Q4 2024.","Net loss narrowed to $0.71M from $0.85M YoY; EBITDA loss also improved to $0.54M.","Reaffirms 2025 revenue guidance of $13M and target of positive EBITDA in 2025.","CEO cites growth in contract manufacturing (Cintas) and consumer branded products; new launches ahead."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":2806000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173035,"accession_number":"0001641172-25-000533","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NexGel adopts new investor presentation; no material disclosures","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company began utilizing a new investor presentation on March 25, 2025.","Presentation filed as Exhibit 99.1 but no substantive financial or operational updates provided.","No guidance, earnings, or material events contained in the 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173034,"accession_number":"0001641172-25-000311","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NexGel Q4 revenue up 181% to $3.04M, guides 2025 revenue of $13M, positive EBITDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $3.04M (up 181% YoY); FY 2024 revenue $8.69M (up 112% YoY).","Gross margin improved to 37.2% in Q4 vs 8.7% a year ago; net loss narrowed to $0.85M from $1.10M.","Cash $1.81M at Dec 31, 2024; guides Q1 2025 revenue at least $2.75M, FY 2025 revenue $13M and positive EBITDA.","Operational: first SilverSeal shipments to Cintas; Silly George run rate >$5M; Stada Histasolv launched."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173033,"accession_number":"0001493152-25-003153","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NEXGEL prelim Q4 rev ~$3M, FY2024 ~$8.6M (+100% YoY); guides FY2025 >$13M, cash flow positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2024 revenue ~$3.0M; full year ~$8.6M, representing >100% YoY growth for third consecutive year.","2025 guidance: at least $13M revenue and positive cash flow from operations during the year.","Silly George run rate grew from $2M to >$5M post-acquisition (May 2024); new beauty under-eye patch planned.","Contract manufacturing added two large international customers; one began Q4 revenue, other expected Q1 2025.","Medagel to launch SilverSeal wound kit and burn pads; Kenkoderm to expand into new indication Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":8688000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173032,"accession_number":"0001493152-25-001000","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"CEO Levy gets $375K salary, 150K options; McGuire named CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Adam Levy's 2025 employment agreement: base salary $375K (up $50K), 26,116 shares grant, 150K stock options at $3.829.","Joseph McGuire appointed CFO effective Jan 1, 2025; salary $200K, 100K stock options at $3.829.","Prior CFO Adam Drapczuk resigns effective Jan 1, 2025; will remain as consultant.","Levy's option vests 37,500 shares annually over 4 years; McGuire's vests over September 2025 and monthly thereafter.","Levy eligible for performance bonuses tied to EBITDA and stock price thresholds up to $75K cash and 115K shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190059,"accession_number":"0001493152-24-045238","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NEXGEL Q3 revenue record $2.94M (+141% YoY); gross margin expands to 43.6%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $754K vs $552K Q3 2023, but improved from $979K Q2 2024; adjusted EBITDA loss narrowed to $347K.","Branded consumer products and contract manufacturing each grew ~100% sequentially.","Cash at Sep 30 was $1.1M; subsequent $2M registered direct offering closed for working capital and inventory.","First SilverSeal orders to Cintas expected in Q4; management guides continued revenue growth and narrowing adjusted EBITDA loss.","Q3 gross profit margin 43.6% vs 28.2% YoY and 28.5% Q2 2024, driven by branded product sales."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":5647000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190058,"accession_number":"0001493152-24-044582","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"NEXGEL raises ~$2M in registered direct offering of stock and warrants at $2.75/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 727,272 common shares and warrants to buy 363,636 shares at $4.25; gross proceeds ~$2M.","Warrants exercisable immediately, expire in 5 years; exercise price $4.25 per share.","Insiders (management & board) participated; subject to 180-day lock-up from closing.","Proceeds to increase inventory, marketing for Silly George, support receivables, and pursue acquisitions.","Alere Financial acted as exclusive placement agent; offering made under existing S-3 shelf."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190057,"accession_number":"0001493152-24-042603","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NexGel adopts new investor presentation (Oct 2024); content not disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed under Item 7.01 Regulation FD; presentation attached as Exhibit 99.1.","No financial or operational details from presentation available in filing text.","Company trades on Nasdaq under NXGL (common) and NXGLW (warrants)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190056,"accession_number":"0001493152-24-040673","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NexGel preannounces record Q3 2024 revenue of $2.85M, +133% YoY, +98% QoQ","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Expected revenue $2.85M, up 133% YoY and 98% sequentially, beating prior $2.20M guidance by ~30%.","Branded consumer sales across all three brands led by Silly George drove growth; contract manufacturing normalized after expansion.","First SilverSeal order to Cintas expected to deliver in Q4 2024.","Full Q3 financial results to be reported on or before November 14, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":5647000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206557,"accession_number":"0001493152-24-032340","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NEXGEL reports record Q2 revenue of $1.44M, net loss widens to $979K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q2 revenue $1.44M, up 23.4% YoY; gross margin improved to 28.5% from 15.0%.","Net loss $979K vs $642K YoY; SG&A up 57.4% due to marketing for Kenkoderm and Silly George.","Issued Q3 guidance $2.2M (+83% YoY) and Q4 $2.6M (+140% YoY).","Closed $1.11M insider-led registered direct offering for working capital to meet Silly George demand.","Cash balance $1.1M as of June 30, 2024; believes sufficient to operate into 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":2706000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206556,"accession_number":"0001493152-24-031687","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"NEXGEL announces $1.11M registered direct offering of 444K shares and 222K warrants; insiders participate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$1.11M from sale of 444K shares at $2.50/share and warrants exercisable at $4.25.","Insiders (board and management) purchased 27K units, subject to 180-day lock-up.","Net proceeds for working capital, including to support Silly George acquisition and inventory/marketing for higher demand.","Offering expected to close on or about August 14, 2024.","Placement agent Alere Financial receives 8% fee from non-affiliates, 4% from affiliates, plus 33,360-share warrant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206555,"accession_number":"0001493152-24-029377","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NexGel begins using new investor presentation as of July 29, 2024","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["New investor presentation adopted on July 29, 2024; content not disclosed in the 8-K.","Tickers impacted: NXGL (common stock) and NXGLW (warrants).","No specific financial guidance, strategic updates, or operational metrics provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206554,"accession_number":"0001493152-24-026484","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NexGel reports preliminary Q2 revenue of $1.4M (+20% YoY); guides Q3 $2.2M, Q4 $2.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 2024 revenue of $1.4M, up ~20% YoY and ~10% sequentially.","Q3 2024 revenue guidance of $2.2M (+83% YoY); Q4 guidance of $2.6M (+140% YoY).","Growth driven by new contract manufacturing relationships with large global corporations and Silly George Pop-On Lash launch.","Company expects to achieve positive cash flow from operations in H2 2024, with AbbVie revenue not yet included in guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":2706000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223730,"accession_number":"0001493152-24-024141","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NexGel stockholders elect five directors, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected: Glassman (1,537,898 For), Henry (1,517,779), Levy (1,537,898), Stein (1,380,100), Zeldis (1,489,435).","Auditor ratification: Turner, Stone & Company ratified with 3,580,246 For, 8,796 Against, 23 Abstaining.","Quorum of 3,589,065 shares (57.6% of 6,227,624 outstanding) present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223729,"accession_number":"0001493152-24-020524","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["1.01","2.01","3.02","8.01","9.01"],"status":"ready","headline":"NexGel acquires Silly George beauty brand for $600k cash+stock plus earn-out","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price: $400k cash, $200k in NXGL common stock, and a 4-year net profit earn-out.","Silly George has ~$2M annual revenue run rate; sells eye/eyelash products via DTC and Amazon.","Seller's management remains; inventory provided at cost post-sale.","Acquisition adds 88k Facebook, 83k Instagram followers, and 254k customer emails for cross-selling.","CEO cites immediate operational synergies and step toward profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223728,"accession_number":"0001493152-24-018955","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NEXGEL Q1 revenue $1.27M (+104% YoY); net loss $905K vs $807K YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue increased 104% to $1.27M, driven by contract manufacturing (+58%) and branded products (+178%).","Gross profit turned positive to $277K from a loss of $57K YoY; gross margin 21.9% vs negative 9.2%.","Net loss widened to $905K from $807K; SG&A up 43.8% to $1.1M on higher advertising and consulting costs.","Cash balance $2.4M as of March 31, 2024, including ~$1M insider-led registered direct offering.","Capacity expansion in Texas nearly complete; product launches with Abbvie and European market entry expected."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":1266000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223727,"accession_number":"0001493152-24-012173","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NEXGEL reports FY2023 revenue $4.1M (+99.7% YoY); net loss narrows to $3.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.1M for FY2023, up 99.7% YoY; Q4 revenue $1.1M, up 110% YoY.","Net loss $3.2M vs $4.7M prior year; gross profit margin improved to 15.2% from 12.5%.","Ended FY2023 with $2.7M cash; subsequent $1M insider-led direct offering closed.","Q1 2024 revenue guided to ~$1.25M, excluding $176K AbbVie deposit.","Key operational milestones: JV with CG Converting, AbbVie gel pad supply agreement, Kenkoderm acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":1266000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243140,"accession_number":"0001493152-24-007399","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"NEXGEL raises ~$975k in registered direct offering led by insiders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering consists of 462,090 shares and warrants to buy 231,040 shares at $4.00, priced at $2.11 per share.","Insiders including CFO and board members purchased 41,469 units; locked up for 180 days.","Gross proceeds ~$975k before expenses; proceeds for working capital and general corporate purposes.","Placement agent Alere Financial receives 6% fee on non-affiliate proceeds and 27,725 warrant shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243139,"accession_number":"0001493152-24-004422","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NexGel begins using new January 2024 investor presentation; no specific details released","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["NexGel announced it began using a new investor presentation dated January 2024.","No financial results, guidance, or operational updates were provided in the filing.","The presentation's specific content is not summarized; investors must review the exhibit directly.","No material changes to company's business or strategy were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243138,"accession_number":"0001493152-24-002447","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Board member Miranda J. Toledano resigns effective March 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Miranda J. Toledano notified NexGel on January 9, 2024 of her resignation from the Board effective March 31, 2024.","She serves as Chairperson of the Audit Committee and member of the Nominating and Corporate Governance Committee.","Resignation is not due to any disagreement with the Company or its subsidiaries.","Company intends to replace her on both committees with other independent Board members effective April 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260531,"accession_number":"0001493152-23-046588","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"NexGel enters 2024 employment agreement with CEO Adam Levy, appoints Scott Henry to compensation committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["NexGel entered a one-year employment agreement with CEO Adam Levy, effective Jan 1, 2024, with $325,000 base salary and $70,000 equity grant.","Performance bonuses include $100,000 cash and 35,000 shares upon achieving positive EBITDA for two consecutive quarters through Q1 2025.","Stock price bonuses: $25,000 cash and 25,000 shares if stock averages $4.50; $75,000 cash and 50,000 shares if $7.00 over three months.","Board appointed Scott R. Henry as Chair of Compensation Committee effective Jan 1, 2024, replacing David Stefansky.","Equity grants issued under Section 4(a)(2) exemption; non-competition and non-solicitation clauses apply to Levy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260530,"accession_number":"0001493152-23-044576","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director David Stefansky resigns from NexGel board effective Dec 31, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Stefansky notified the company on Dec 7, 2023 of his resignation from the Board, effective Dec 31, 2023.","He served as Chairperson of the Compensation Committee and member of the Nominating and Corporate Governance Committee.","The resignation is not due to any disagreement with the company; he is leaving to pursue other business ventures.","No replacement for the departing director has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260529,"accession_number":"0001493152-23-044321","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NEXGEL forms partnership with STADA to distribute OTC health products in North America starting mid-2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Partnership with STADA Arzneimittel AG, a European consumer health leader, for distribution and commercialization.","Product launch expected mid-2024; brings established European OTC products to North American consumers.","STADA reported 2022 group sales of EUR 3,797.2 million and EBITDA of EUR 884.7 million.","NEXGEL will leverage its hydrogel expertise and contract manufacturing for the partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260528,"accession_number":"0001493152-23-043659","cik":1468929,"company_name":"NEXGEL, INC.","ticker":"NXGL","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["1.01","2.01","8.01","9.01"],"status":"ready","headline":"NexGel acquires Kenkoderm psoriasis skincare line for $546,500 initial cash plus earn-out","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Initial cash payment of $546,500; earn-out up to additional $546,500 based on 2024 performance.","Kenkoderm is profitable for trailing twelve months and expected to be immediately accretive to NXGL.","Deal includes 3-year non-compete from Seller; Kenkoderm has 6 SKUs sold via e-commerce and Amazon.","Acquisition closed December 1, 2023; no shareholder approval required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7123361.5209125485,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-12-05T23:59:59+00:00|260528"}